Daiichi Sankyo Reports the First Patient Dosing of Datopotamab Deruxtecan in P-III Trial (TROPION-Lung07) for Metastatic Non-Small Cell Lung Cancer
- The first patient has been dosed in the P-III trial (TROPION-Lung07) evaluating datopotamab deruxtecan (Dato-DXd) + pembrolizumab with/out Pt CT in a ratio (1:1:1) in 975 patients with advanced or metastatic NSCLC with PD-L1 expression 50% & without actionable genomic alterations at sites in North America, South America, EU, Asia & Oceania
- Datopotamab deruxtecan is being jointly developed by Daiichi Sankyo & AstraZeneca. The 1EPs of the study are PFS & OS while 2EPs incl. ORR, DoR, time to response, DCR, PFS, PFS2 & safety
- Datopotamab deruxtecan is a TROP2-directed ADC & is being developed by using DXd ADC technology. Early trials, incl. (TROPION-Lung02) demonstrated increased activity & manageable safety profile for the combination therapy with/out CT
Ref: Businesswire | Image: Daiichi Sankyo
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.